[Featured Stock] Somagen, Large-Scale Investment in US mRNA Cancer Vaccine... Spotlight on Genomic Analysis for Moderna Up↑

SomaGen is showing strong performance. This is interpreted as being influenced by the announcement that the United States will invest in a cancer vaccine development project using messenger ribonucleic acid (mRNA) technology, which made groundbreaking progress during the development of the COVID-19 vaccine.

As of 10:59 AM on the 24th, SomaGen is trading at 6,350 KRW, up 9.66% compared to the previous day.

The day before, U.S. President Joe Biden's cancer conquest project, "Cancer Moonshot," announced that it will invest $24 million in Emory University's "CUREIT," which uses mRNA technology to combat cancer and other diseases. mRNA, which acts as a kind of blueprint that instructs the body on how to produce proteins, has gained significant attention since the COVID-19 pandemic.

President Biden stated, "We have launched the 'Cancer Moonshot' project to end cancer," and emphasized, "Today, we have taken an important step toward this goal. We will develop technology that enhances our immune system to fight cancer using mRNA technology."

Meanwhile, Moderna is a global vaccine development company that developed the mRNA-based COVID-19 vaccine. SomaGen succeeded in securing an extension contract for genome sequencing services worth approximately $6.48 million (8.5 billion KRW) for one year starting from the second half of this year with Moderna, a world-renowned vaccine development company, in July, raising expectations for revenue recovery in the second half of the year.

Moderna has maintained a close partnership with SomaGen for about 10 years since 2014, increasing order volumes, and it is reported that in the recent extension contract, Moderna was satisfied with SomaGen's analysis speed and accuracy, expanding the supply volume to more than double compared to last year.

This content was produced with the assistance of AI translation services.